Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06792253 is registered in ClinicalTrials.gov with BeBetter Med Inc as lead sponsor.

NCT NCT06792253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06792253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ⅲ Clinical Trial Comparing BEBT-908 Combined With Rituximab (R) to Standard of Care for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Lead sponsor
BeBetter Med Inc
Phase
Phase 3
Overall status
Recruiting
Start date
January 6, 2025
Completion date
June 30, 2029
Enrollment
416 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b-cell lymphoma